STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more

STAT PlusNewsletterPharmalot Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more U.K. ​drug regulator authorizes Lilly’s Foundayo for weight ​management and type ​2 diabetes Manage alerts for this article Email this article Share this article By Ed SilvermanAug. 10, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation.

He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance.

You knew this would happen, yes? To cope, we are relying, as always, on a cuppa stimulation. Our choice today is honeybush vanilla turmeric.

Feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along.

Best of luck accomplishing your goals today and, of course, do keep in touch. … Sanofi is experiencing shortages of two medicines used to treat Pompe disease, and the problem emerged shortly after the U.S. Food and Drug Administration warned the company over manufacturing issues at the Irish facility where the drugs are made, STAT reports.

In recent days, the drugmaker has alerted patient groups and physicians in both the U.S. and Europe that supplies of Myozyme, an older standard of care, and Nexviazyme, a newer treatment, are dwindling due to what has been described as a bottleneck in the final manufacturing phase, as well as quality control issues at its Waterford plant.Advertisement Jazz Pharmaceuticals agreed to buy Actio Biosciences in a deal valued at ​up to $1.32 billion, adding an experimental treatment for ‌a rare inherited form of epilepsy that has no approved therapies, Reuters notes. The treatment, called ABS-1230, is being developed for KCNT1-related epilepsy, ​a severe disease that causes frequent seizures ​and developmental problems in children.

KCNT1-related epilepsy affects about ​2,500 patients in the U.S., according to the company. ABS-1230 reduced seizures in ‌an ⁠early study of children and is being evaluated in a study intended to support a U.S. approval application.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account?

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.

Subscribe Log In pharmalittle, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Exclusive August 9, 2026 STAT Plus: A shortage of two Sanofi medicines for Pompe disease rattles patients Pharmalot August 7, 2026 STAT Plus: Up and down the ladder: The latest comings and goings Advertisement August 7, 2026 STAT Plus: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more Pharmalot August 6, 2026 STAT Plus: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts Pharmalot August 6, 2026 STAT Plus: Pharmalittle: We’re reading about Moderna’s flu shot, a death in a gene-editing trial in China, and more Subscriber Picks